Literature DB >> 3929441

Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.

C J Logothetis, M L Samuels, S Ogden.   

Abstract

Eight patients with unresectable adenocarcinoma of the bladder or urachus were treated with chemotherapy. Four had received cisplatin-based chemotherapy (CISCA), all 4 failed to respond. All 8 received intravenous and/or intra-arterial 5-fluorouracil, doxorubicin hydrochloride (Adriamycin), and mitomycin-C. Three of the 5 responding patients had short responses while 2 had achieved long-term control of disease. One is in complete remission for eleven plus months, and 1 patient had a partial remission of nineteen plus months. Five patients had serum CEA levels measured at presentation. In the 3 patients with an elevated CEA at presentation who responded to chemotherapy a corresponding drop in the initial level was seen. 5-Fluorouracil-based chemotherapy is effective in the management of adenocarcinoma of the bladder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929441     DOI: 10.1016/0090-4295(85)90121-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

Review 1.  Current Understanding of Urachal Adenocarcinoma and Management Strategy.

Authors:  Mélanie Claps; Marco Stellato; Emma Zattarin; Alessia Mennitto; Pierangela Sepe; Valentina Guadalupi; Roberta Mennitto; Filippo G M de Braud; Elena Verzoni; Giuseppe Procopio
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  Successful chemotherapy in a patient with recurrent carcinoma of the urachus.

Authors:  O Ichiyanagi; I Sasagawa; Y Suzuki; Y Iijima; Y Kubota; T Nakada; S Arai
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

3.  Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.

Authors:  Minyuen Teo; Niall C Swan; Ray S McDermott
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

4.  Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature.

Authors:  Jorg Michels; Sean Barbour; Douglas Cavers; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

5.  A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.

Authors:  Christine Elser; Joan Sweet; Sendhil K Cheran; Masoom A Haider; Michael Jewett; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

Review 6.  Chemotherapy for bladder cancer in patients with impaired renal function.

Authors:  Steve Nicholson
Journal:  Nat Rev Urol       Date:  2011-11-22       Impact factor: 14.432

7.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.

Authors:  Somak Roy; Dinesh Pradhan; Wayne L Ernst; Stephanie Mercurio; Yana Najjar; Rahul Parikh; Anil V Parwani; Reetesh K Pai; Rajiv Dhir; Marina N Nikiforova
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

8.  Treatment of metastatic urachal adenocarcinoma in a young woman: a case report.

Authors:  Elmehdi Tazi; Issam Lalya; Mohammed Fadl Tazi; Youness Ahallal; Hind M'rabti; Hassan Errihani
Journal:  Cases J       Date:  2009-12-04

Review 9.  Carcinoma of the urachus. A case report and review of the literature.

Authors:  T E Johansen; P W Jebsen
Journal:  Int Urol Nephrol       Date:  1993       Impact factor: 2.370

10.  Trends of incidence and prognosis of primary adenocarcinoma of the bladder.

Authors:  Haowen Lu; Weidong Zhu; Weipu Mao; Feng Zu; Yali Wang; Wenchao Li; Bin Xu; Lihua Zhang; Ming Chen
Journal:  Ther Adv Urol       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.